Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S1UZ
|
|||
| Former ID |
DIB007150
|
|||
| Drug Name |
PD-360324
|
|||
| Synonyms |
PD-0360324; MCSF mAb (RA), Pfizer; Macrophage colony stimulating factor monoclonal antibody (rheumatoid arthritis), Pfizer
Click to Show/Hide
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [1] | |
| Company |
Pfizer
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Colony stimulating factor-1 receptor (CSF-1R) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01732211) A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis. U.S. National Institutes of Health. | |||
| REF 2 | Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.Clin Exp Immunol.2016 Feb;183(2):258-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.